keyword
MENU ▼
Read by QxMD icon Read
search

Malaria vaccine

keyword
https://www.readbyqxmd.com/read/28533429/fibrinogen-domain-of-frep1-is-a-broad-spectrum-malaria-transmission-blocking-vaccine-antigen
#1
Guodong Niu, Caio Franca, Genwei Zhang, Wanlapa Roobsoong, Wang Nguitragool, Xiaohong Wang, Jetsumon Prachumsri, Noah S Butler, Jun Li
FREP1 in mosquito midguts facilitates P. falciparum parasite transmission. Fibrinogen-like (FBG) domain of FREP1 is highly conserved (>90% identical) among Anopheles species from different continents, suggesting that anti-FBG antibodies may block malaria transmission to all anopheline mosquitoes. Using standard membrane-feeding assays, anti-FREP1 polyclonal antibodies significantly blocked transmission of P. berghei and P. vivax to An. gambiae and An. dirus respectively. Furthermore, in vivo studies of mice immunized with FBG achieved >75% blocking efficacy of P...
May 22, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/28531172/experimental-evaluation-of-cryopreservative-solutions-to-maintain-in-vitro-and-in-vivo-infectivity-of-p-berghei-sporozoites
#2
Naresh Singh, Samantha J Barnes, Sandra Kennedy, John H Adams
The rodent malaria parasite Plasmodium berghei is an excellent model organism for laboratory-based experimental evaluation of anti-malarial therapeutics prior to studies with human malaria parasites. The rodent model is especially important for evaluation of pre-erythrocytic (PE) stage therapies, especially as current efforts to develop new PE vaccines and drugs is limited by access to P. falciparum and P. vivax sporozoites. Developing a more effective method for cryopreservation of sporozoites would help improve access to sporozoites for laboratories lacking suitable insectary facilities...
2017: PloS One
https://www.readbyqxmd.com/read/28527688/clinical-development-of-a-var2csa-based-placental-malaria-vaccine-pamvac-quantifying-vaccine-antigen-specific-memory-b-t-cell-activity-in-beninese-primigravidae
#3
Komi Gbédandé, Nadine Fievet, Firmine Viwami, Sem Ezinmegnon, Saadou Issifou, Jean-Philippe Chippaux, Yannelle Dossou, Kabirou Moutairou, Achille Massougbodji, Nicaise Ndam, Willem Adriaan de Jongh, T Max M Søgaard, Ali Salanti, Morten A Nielsen, Meral Esen, Benjamin Mordmüller, Philippe Deloron, Adrian J F Luty
BACKGROUND: The antigen VAR2CSA plays a pivotal role in the pathophysiology of pregnancy-associated malaria (PAM) caused by Plasmodium falciparum. A VAR2CSA-based vaccine candidate, PAMVAC, is under development by an EU-funded multi-country consortium (PlacMalVac project). As part of PAMVAC's clinical development, we quantified naturally acquired vaccine antigen-specific memory B and T cell responses in Beninese primigravidae recruited at the beginning of pregnancy and followed up to delivery and beyond...
May 17, 2017: Vaccine
https://www.readbyqxmd.com/read/28526680/decrease-in-numbers-of-naive-and-resting-b-cells-in-hiv-infected-kenyan-adults-leads-to-a-proportional-increase-in-total-and-plasmodium-falciparum-specific-atypical-memory-b-cells
#4
Anne E Frosch, Oludare A Odumade, Justin J Taylor, Kathleen Ireland, George Ayodo, Bartholomew Ondigo, David L Narum, John Vulule, Chandy C John
Human immunodeficiency virus type 1 (HIV-1) infection is associated with B cell activation and exhaustion, and hypergammaglobulinemia. How these changes influence B cell responses to coinfections such as malaria is poorly understood. To address this, we compared B cell phenotypes and Abs specific for the Plasmodium falciparum vaccine candidate apical membrane Ag-1 (AMA1) in HIV-infected and uninfected adults living in Kenya. Surprisingly, HIV-1 infection was not associated with a difference in serum AMA1-specific Ab levels...
May 19, 2017: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/28525963/the-use-of-transgenic-parasites-in-malaria-vaccine-research
#5
Ahmad Syibli Othman, Catherin Marin-Mogollon, Ahmed M Salman, Blandine M Franke-Fayard, Chris J Janse, Shahid M Khan
Transgenic malaria parasites expressing foreign genes, for example fluorescent and luminescent proteins, are used extensively to interrogate parasite biology and host-parasite interactions associated with malaria pathology. Increasingly transgenic parasites are also exploited to advance malaria vaccine development. Areas Covered: We review how transgenic malaria parasites are used, in vitro and in vivo, to determine protective efficacy of different antigens and vaccination strategies and to determine immunological correlates of protection...
May 19, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28515133/development-of-a-novel-virus-like-particle-vaccine-platform-that-mimics-immature-form-of-alphavirus
#6
Akane Urakami, Atsuko Sakurai, Momoko Ishikawa, Moh Lan Yap, Yevel Flores-Garcia, Yasunari Haseda, Taiki Aoshi, Fidel P Zavala, Michael G Rossmann, Sachiko Kuno, Ryuji Ueno, Wataru Akahata
Virus-like particles (VLPs) are non-infectious multiprotein structures that are engineered to self-assemble from viral structural proteins. Here, we developed a novel VLP-based vaccine platform utilizing VLPs from the Chikungunya virus. We identified two regions within the envelope protein, a structural component of Chikungunya, where foreign antigens can be inserted without compromising VLP structure. Our VLP displays 480 copious copies of an inserted antigen on the VLP surface in a highly symmetric manner, thus capable of inducing strong immune responses against any inserted antigen...
May 17, 2017: Clinical and Vaccine Immunology: CVI
https://www.readbyqxmd.com/read/28507198/modern-vector-control
#7
Neil F Lobo, Nicole L Achee, John Greico, Frank H Collins
The rapid spread of mosquito resistance to currently available insecticides, and the current lack of an efficacious malaria vaccine are among many challenges that affect large-scale efforts for malaria control. As goals of malaria elimination and eradication are put forth, new vector-control paradigms and tools and/or further optimization of current vector-control products are required to meet public health demands. Vector control remains the most effective measure to prevent malaria transmission and present gains against malaria mortality and morbidity may be maintained as long as vector-intervention strategies are sustained and adapted to underlying vector-related transmission dynamics...
May 15, 2017: Cold Spring Harbor Perspectives in Medicine
https://www.readbyqxmd.com/read/28505356/distinct-th1-and-th2-cellular-responses-associated-with-malaria-protection-and-risk-in-rts-s-as01e-vaccinees
#8
Gemma Moncunill, Maxmillian Mpina, Augusto J Nhabomba, Ruth Aguilar, Aintzane Ayestaran, Héctor Sanz, Joseph J Campo, Chenjerai Jairoce, Diana Barrios, Yan Dong, Núria Díez-Padrisa, José F Fernandes, Salim Abdulla, Jahit Sacarlal, Nana A Williams, Jaroslaw Harezlak, Benjamin Mordmüller, Selidji T Agnandji, John J Aponte, Claudia Daubenberger, Clarissa Valim, Carlota Dobaño
Background.: The RTS,S/AS01E malaria vaccine has moderate efficacy, lower in infants than children. Current efforts to enhance RTS,S/AS01E efficacy would benefit from learning about the vaccine-induced immunity and identifying correlates of malaria protection, which could, for instance, inform the choice of adjuvants. Here, we sought cellular immunity-based correlates of malaria protection and risk associated with RTS,S/AS01E vaccination. Methods.: We performed a matched case-control study nested within the multicenter African RTS,S/AS01E Phase III trial...
May 13, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28500775/vaccines-against-malaria-still-a-long-way-to-go
#9
REVIEW
Kai Matuschewski
Several species of Plasmodium cause a broad spectrum of human disease that range from nausea and fever to severe anemia, cerebral malaria, and multi-organ failure. In malaria-endemic countries continuous exposure to Plasmodium sporozoite inoculations and subsequent blood infections elicit only partial and short-lived immunity, which gradually develops over many years of parasite exposure and multiple clinical episodes. The ambitious goal of malaria vaccinology over the past 70 years has been to develop an immunization strategy that mounts protection superior to naturally acquired immunity...
May 13, 2017: FEBS Journal
https://www.readbyqxmd.com/read/28493930/clinical-laboratory-reference-values-amongst-children-aged-4-weeks-to-17-months-in-kilifi-kenya-a-cross-sectional-observational-study
#10
Jesse Gitaka, Caroline Ogwang, Moses Ngari, Pauline Akoo, Ally Olotu, Christine Kerubo, Greg Fegan, Patricia Njuguna, Godfrey Nyakaya, Tuda Otieno, Gabriel Mwambingu, Ken Awuondo, Brett Lowe, Roma Chilengi, James A Berkley
Reference intervals for clinical laboratory parameters are important for assessing eligibility, toxicity grading and management of adverse events in clinical trials. Nonetheless, haematological and biochemical parameters used for clinical trials in sub-Saharan Africa are typically derived from industrialized countries, or from WHO references that are not region-specific. We set out to establish community reference values for haematological and biochemical parameters amongst children aged 4 weeks to 17 months in Kilifi, Kenya...
2017: PloS One
https://www.readbyqxmd.com/read/28490540/the-biology-of-plasmodium-vivax
#11
John H Adams, Ivo Mueller
Plasmodium vivax is the second most prevalent cause of malaria worldwide and the leading cause of malaria outside of Africa. Although infections are seldom fatal clinical disease can be debilitating and imposes significant health and economic impacts on affected populations. Estimates of transmission and prevalence intensity can be problematic because many episodes of vivax originate from hypnozoite stages in the liver that have remained dormant from previous infections by an unknown mechanism. Lack of treatment options to clear hypnozoites and the ability to infect mosquitoes before disease symptoms present represent major challenges for control and eradication of vivax malaria...
May 10, 2017: Cold Spring Harbor Perspectives in Medicine
https://www.readbyqxmd.com/read/28490535/vaccines-to-accelerate-malaria-elimination-and-eventual-eradication
#12
Julie Healer, Alan F Cowman, David C Kaslow, Ashley J Birkett
Remarkable progress has been made in coordinated malaria control efforts with substantial reductions in malaria-associated deaths and morbidity achieved through mass administration of drugs and vector control measures including distribution of long-lasting insecticide-impregnated bednets and indoor residual spraying. However, emerging resistance poses a significant threat to the sustainability of these interventions. In this light, the malaria research community has been charged with the development of a highly efficacious vaccine to complement existing malaria elimination measures...
May 10, 2017: Cold Spring Harbor Perspectives in Medicine
https://www.readbyqxmd.com/read/28490424/waning-immunity-and-microbial-vaccines-workshop-of-the-national-institute-of-allergy-and-infectious-diseases
#13
Xin-Xing Gu, Stanley A Plotkin, Kathryn M Edwards, Alessandro Sette, Kingston H G Mills, Ofer Levy, Andrea J Sant, Annie Mo, William Alexander, Kristina T Lu, Christopher E Taylor
Since the middle of the 20th century, vaccines have made a significant public health impact controlling infectious diseases globally. Although long-term protection has been achieved with some vaccines, immunity wanes over time with others, resulting in outbreaks or epidemics of infectious diseases. Long-term protection against infectious agents with complex life cycles and antigenic variation remains a key challenge. Novel strategies to characterize the short and long-term immune responses to vaccines, and to induce immune responses that mimic natural infection have recently emerged...
May 10, 2017: Clinical and Vaccine Immunology: CVI
https://www.readbyqxmd.com/read/28483199/a-prime-boost-immunization-regimen-based-on-a-simian-adenovirus-36-vectored-multi-stage-malaria-vaccine-induces-protective-immunity-in-mice
#14
Jairo A Fonseca, Jessica N McCaffery, Elena Kashentseva, Balwan Singh, Igor P Dmitriev, David T Curiel, Alberto Moreno
Malaria remains a considerable burden on public health. In 2015, the WHO estimates there were 212 million malaria cases causing nearly 429,000 deaths globally. A highly effective malaria vaccine is needed to reduce the burden of this disease. We have developed an experimental vaccine candidate (PyCMP) based on pre-erythrocytic (CSP) and erythrocytic (MSP1) stage antigens derived from the rodent malaria parasite P. yoelii. Our protein-based vaccine construct induces protective antibodies and CD4(+) T cell responses...
May 31, 2017: Vaccine
https://www.readbyqxmd.com/read/28483194/co-localization-of-a-cd1d-binding-glycolipid-with-an-adenovirus-based-malaria-vaccine-for-a-potent-adjuvant-effect
#15
Xiangming Li, Jing Huang, Akira Kawamura, Ryota Funakoshi, Steven A Porcelli, Moriya Tsuji
A CD1d-binding, invariant (i) natural killer T (NKT)-cell stimulatory glycolipid, α-Galactosylceramide (αGalCer), has been shown to act as an adjuvant. We previously identified a fluorinated phenyl ring-modified αGalCer analog, 7DW8-5, displaying a higher binding affinity for CD1d molecule and more potent adjuvant activity than αGalCer. In the present study, 7DW8-5 co-administered intramuscularly (i.m.) with a recombinant adenovirus expressing a Plasmodium yoelii circumsporozoite protein (PyCSP), AdPyCS, has led to a co-localization of 7DW8-5 and a PyCSP in draining lymph nodes (dLNs), particularly in dendritic cells (DCs)...
May 31, 2017: Vaccine
https://www.readbyqxmd.com/read/28479181/carbohydrate-fatty-acid-monosulphate-esters-are-safe-and-effective-adjuvants-for-humoral-responses
#16
Luuk A Th Hilgers, Peter Paul L I Platenburg, Jeffrey Bajramovic, Jennifer Veth, Robert Sauerwein, Will Roeffen, Marie Pohl, Geert van Amerongen, Koert J Stittelaar, Johannes F van den Bosch
Carbohydrate fatty acid sulphate esters (CFASEs) formulated in a squalane-in-water emulsion are effective adjuvants for humoral responses to a wide range of antigens in various animal species but rise in body temperature and local reactions albeit mild or minimal hampers application in humans. In rabbits, body temperature increased 1°C one day after intramuscular (IM) injection, which returned to normal during the next day. The effect increased with increasing dose of CFASE but not with the number of injections (up to 5)...
May 31, 2017: Vaccine
https://www.readbyqxmd.com/read/28479180/accelerated-and-long-term-stability-study-of-pfs25-epa-conjugates-adjuvanted-with-alhydrogel%C3%A2
#17
Daming Zhu, Yimin Wu, Holly McClellan, Weili Dai, Kelly Rausch, Dominique Jones, Joan Aebig, Emma Barnafo, Brandi Butler, Lynn Lambert, David L Narum, Patrick E Duffy
Pfs25, a Plasmodium falciparum surface protein expressed during zygote and ookinete stages in infected mosquitoes, is a lead transmission-blocking vaccine candidate against falciparum malaria. To enhance immunogenicity, recombinant Pfs25 was chemically conjugated to recombinant nontoxic Pseudomonas aeruginosa ExoProtein A (rEPA) in conformance with current good manufacturing practices (cGMP), and formulated with the alum adjuvant Alhydrogel. In order to meet the regulatory requirements for a phase 1 human clinical trial, the vaccine product was extensively evaluated for stability at an initial time point and through the clinical trial period annually...
May 31, 2017: Vaccine
https://www.readbyqxmd.com/read/28470856/defining-health-research-for-development-the-perspective-of-stakeholders-from-an-international-health-research-partnership-in-ghana-and-tanzania
#18
Claire Leonie Ward, David Shaw, Evelyn Anane-Sarpong, Osman Sankoh, Marcel Tanner, Bernice Elger
OBJECTIVES: The study uses a qualitative empirical method to define Health Research for Development. This project explores the perspectives of stakeholders in an international health research partnership operating in Ghana and Tanzania. METHODS: We conducted 52 key informant interviews with major stakeholders in an international multicenter partnership between GlaxoSmithKline (GSK, Vaccine Developer) and the global health nonprofit organisation PATH and its Malaria Vaccine Initiative program (PATH/MVI, Funder-Development Partner), (RTS, S) (NCT00866619)...
May 3, 2017: Developing World Bioethics
https://www.readbyqxmd.com/read/28468980/identification-of-protective-b-cell-epitopes-within-the-novel-malaria-vaccine-candidate-p-falciparum-schizont-egress-antigen-1
#19
Christina E Nixon, Sangshin Park, Sunthorn Pond-Tor, Dipak Raj, Lynn E Lambert, Sachy Orr-Gonzales, Emma K Barnafo, Jennifer F Friedman, Michal Fried, Patrick E Duffy, Jonathan D Kurtis
Naturally-acquired antibodies to PfSEA-1A are associated with protection against severe malaria in children. Vaccination of mice with PbSEA-1A decreases parasitemia and prolongs survival following Plasmodium berghei ANKA challenge. To enhance the immunogenicity of PfSEA-1A, we identified five linear, B-cell epitopes using peptide microarrays probed with anti-sera from rPfSEA-1A-vaccinated non-human primates. We evaluated the relationship between epitope-specific antibody levels and protection from parasitemia in a longitudinal treatment-reinfection cohort in Western Kenya...
May 3, 2017: Clinical and Vaccine Immunology: CVI
https://www.readbyqxmd.com/read/28468322/virus-like-particle-vlp-plus-microcrystalline-tyrosine-mct-adjuvants-enhance-vaccine-efficacy-improving-t-and-b-cell-immunogenicity-and-protection-against-plasmodium-berghei-vivax
#20
Gustavo Cabral-Miranda, Matthew D Heath, Mona O Mohsen, Ariane C Gomes, Paul Engeroff, Amy Flaxman, Fabiana M S Leoratti, Aadil El-Turabi, Arturo Reyes-Sandoval, Murray A Skinner, Matthias F Kramer, Martin F Bachmann
Vaccination is the most effective prophylactic tool against infectious diseases. Despite continued efforts to control malaria, the disease still generally represents a significant unmet medical need. Microcrystalline tyrosine (MCT) is a well described depot used in licensed allergy immunotherapy products and in clinical development. However, its proof of concept in prophylactic vaccines has only recently been explored. MCT has never been used in combination with virus-like particles (VLPs), which are considered to be one of the most potent inducers of cellular and humoral immune responses in mice and humans...
May 2, 2017: Vaccines
keyword
keyword
2342
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"